港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

映恩生物-B

204.600

-21.000-9.31%

成交量：171.06萬

成交額：3.65億

市值：185.11億

市盈率：-4.44

高：235.000

開：235.000

低：202.000

收：225.600

52周最高：563.500

52周最低：188.100

股本：9,047.56萬

香港流通股本：9,047.56萬

量比：1.87

換手率：1.89%

股息：- -

股息率：- -

每股收益(LYR):-46.117

淨資產收益率：-1282.14%

總資產收益率：-9.61%

市淨率：6.58

市盈率(LYR):-4.44

市銷率: 8.63

資料載入中...

總覽公司新聞資訊公告

中金：國家優化創新藥新藥上市首發價格機制藥品行業有望迎高質量發展

映恩生物－Ｂ(09606)股價上升8.089%，現價港幣$310.0

阿斯达克财经

異動解讀 | 映恩生物-B盤中大漲5.02%，科創板上市計劃提振市場信心

加速全球ADC龍頭價值構建，映恩生物-B(09606)推動「H+A」雙資本平台佈局釋放長投信號

映恩生物－Ｂ(09606)出現大手賣出1.77萬股，成交價$287.0，涉資507.99萬

阿斯达克财经

映恩生物-B(09606)擬發行人民幣股份於科創板上市募資不超過67.5億元

智通财经网

映恩生物-B：人民幣股份發行所得款項將用於創新藥物研發等用途

【券商聚焦】海通國際維持映恩生物-B(09606)「優於大市」評級指其核心管線商業化臨近

《大行》海通國際予映恩生物(09606.HK)目標價457.74元評級「優於大市」

阿斯达克财经

映恩生物(09606.HK)核心產品DB-1303/BNT323上市申請獲受理

阿斯达克财经

映恩生物宣佈抗HER2 ADC新藥Trastuzumab Pamirtecan治療晚期乳腺癌的BLA獲中國國家藥監局受理

國家藥監局受理映恩生物DB-1303/BNT323治療HER2陽性乳腺癌的生物製品許可申請

映恩生物-B(09606)：DB-1303/BNT323用於不可切除或轉移性HER2陽性成人乳腺癌的新藥上市申請獲得國家藥監局受理

映恩生物-B3月股份變動月報表，股本小幅增加

映恩生物－Ｂ(09606)出現大手成交300萬股，成交價$301.0，涉資9.03億

阿斯达克财经

異動解讀 | 生物醫藥板塊全線走高帶動，映恩生物-B盤中大漲6.11%

異動解讀 | 中金維持跑贏行業評級，映恩生物-B盤中大漲6.41%

中金：維持映恩生物-B(09606)跑贏行業評級目標價430港元

映恩生物－Ｂ(09606)出現大手賣出6.7萬股，成交價$258.0，涉資1.729千萬

阿斯达克财经

映恩生物(09606.HK)委任首席財務官

阿斯达克财经

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/09606/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09606","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","market":"HK","secType":"STK","nameCN":"映恩生物-B","latestPrice":204.6,"timestamp":1780301307007,"preClose":225.6,"halted":0,"volume":1710564,"delay":0,"changeRate":-0.09308510638297872,"floatShares":90475600,"shares":90475600,"eps":-46.11737613945431,"marketStatus":"未開盤","change":-21,"latestTime":"06-01 16:08:27","open":235,"high":235,"low":202,"amount":364953557,"amplitude":0.146277,"askPrice":204.8,"askSize":100,"bidPrice":204.6,"bidSize":2200,"shortable":3,"etf":0,"ttmEps":-36.930980208962005,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1780363800000},"marketStatusCode":0,"adr":0,"listingDate":1744646400000,"exchange":"SEHK","adjPreClose":225.6,"openAndCloseTimeList":[[1780277400000,1780286400000],[1780290000000,1780300800000]],"volumeRatio":1.872144,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09606\",,,,,undefined,":{"symbol":"09606","floatShares":90475600,"roa":"-9.61%","roe":"-1282.14%","lyrEps":-46.117376,"volumeRatio":1.872144,"shares":90475600,"dividePrice":0,"high":235,"amplitude":0.146277,"preClose":225.6,"low":202,"week52Low":188.1,"pbRate":"6.58","psRate":"8.63","week52High":563.5,"institutionHeld":0,"latestPrice":204.6,"committee":0.913043,"eps":-46.11737613945431,"divideRate":0,"volume":1710564,"delay":0,"ttmEps":-36.930980208962005,"open":235,"prevYearClose":298.2,"prevWeekClose":225.6,"prevMonthClose":225.6,"prevQuarterClose":295,"fiveDayClose":222.8,"twentyDayClose":276,"sixtyDayClose":299},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09606\",params:#limit:5,,,undefined,":[{"date":"2026-03-23","symbol":"09606","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774229400000,"name":null,"time":"","dateTimestamp":1774195200000,"actualEps":null},{"date":"2025-08-26","symbol":"09606","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756171800000,"name":null,"time":"","dateTimestamp":1756137600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09606\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09606\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1761408000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09606\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09606","date":"2026-05-29","current":-5.542819,"percent":0.974545,"low":-29.984477,"twenty":-18.096065,"median":-9.620334,"eighty":-8.669056,"high":-6.033707,"avg":-12.91758,"sd":6.15558,"marketCap":20400514838},"quantilePoints":[{"date":"2025-04-17","current":-14.905978,"twenty":-15.065639,"median":-14.442293,"eighty":-11.334487,"marketCap":16635152800},{"date":"2025-04-25","current":-15.846935,"twenty":-16.770434,"median":-15.576033,"eighty":-14.349556,"marketCap":17719522633},{"date":"2025-05-02","current":-16.438538,"twenty":-16.715855,"median":-16.124153,"eighty":-14.985809,"marketCap":18420101638},{"date":"2025-05-09","current":-15.074661,"twenty":-16.551291,"median":-15.826729,"eighty":-15.074661,"marketCap":17010399982},{"date":"2025-05-16","current":-15.043786,"twenty":-16.438538,"median":-15.220044,"eighty":-14.405796,"marketCap":17114249721},{"date":"2025-05-23","current":-16.495727,"twenty":-16.438538,"median":-15.262587,"eighty":-14.582474,"marketCap":18822153243},{"date":"2025-05-30","current":-16.208434,"twenty":-16.401371,"median":-15.460562,"eighty":-14.726132,"marketCap":18575651704},{"date":"2025-06-06","current":-16.427701,"twenty":-16.438538,"median":-15.666395,"eighty":-14.905978,"marketCap":18874975001},{"date":"2025-06-13","current":-20.940103,"twenty":-16.693343,"median":-15.893657,"eighty":-15.005253,"marketCap":24069114577},{"date":"2025-06-20","current":-18.479443,"twenty":-18.428819,"median":-16.104695,"eighty":-15.043786,"marketCap":21199132371},{"date":"2025-06-27","current":-18.0452,"twenty":-18.863356,"median":-16.282988,"eighty":-15.074661,"marketCap":20758951051},{"date":"2025-07-04","current":-21.227749,"twenty":-18.942282,"median":-16.427701,"eighty":-15.074735,"marketCap":24421259633},{"date":"2025-07-11","current":-22.045806,"twenty":-19.683704,"median":-16.508309,"eighty":-15.190609,"marketCap":25336836779},{"date":"2025-07-18","current":-25.758166,"twenty":-20.839221,"median":-16.693343,"eighty":-15.21995,"marketCap":29580184704},{"date":"2025-07-25","current":-25.970367,"twenty":-21.539184,"median":-16.981252,"eighty":-15.260218,"marketCap":29932329760},{"date":"2025-08-01","current":-24.963588,"twenty":-22.267132,"median":-18.096065,"eighty":-15.298157,"marketCap":28594178547},{"date":"2025-08-08","current":-27.998627,"twenty":-24.402884,"median":-18.454131,"eighty":-15.429476,"marketCap":32150843612},{"date":"2025-08-15","current":-27.487815,"twenty":-25.397092,"median":-18.863356,"eighty":-15.513126,"marketCap":31516982512},{"date":"2025-08-22","current":-26.341915,"twenty":-25.761111,"median":-19.052333,"eighty":-15.750472,"marketCap":30108402288},{"date":"2025-08-29","current":-8.977182,"twenty":-25.761111,"median":-19.118727,"eighty":-15.513126,"marketCap":27784244918},{"date":"2025-09-05","current":-10.341403,"twenty":-25.547361,"median":-18.897362,"eighty":-15.21995,"marketCap":31974771084},{"date":"2025-09-12","current":-12.806892,"twenty":-25.484142,"median":-18.479443,"eighty":-15.036079,"marketCap":39669140558},{"date":"2025-09-19","current":-11.291493,"twenty":-25.397092,"median":-18.151913,"eighty":-14.569138,"marketCap":34950396808},{"date":"2025-09-26","current":-9.575685,"twenty":-25.265241,"median":-17.183112,"eighty":-14.242848,"marketCap":29562577451},{"date":"2025-10-03","current":-9.769092,"twenty":-25.225948,"median":-16.756996,"eighty":-13.467837,"marketCap":30231653057},{"date":"2025-10-10","current":-8.39875,"twenty":-25.201143,"median":-16.551291,"eighty":-12.508489,"marketCap":25953090627},{"date":"2025-10-17","current":-9.52866,"twenty":-25.090759,"median":-16.467132,"eighty":-11.127698,"marketCap":29421719428},{"date":"2025-10-24","current":-8.24833,"twenty":-24.683236,"median":-16.401371,"eighty":-10.383008,"marketCap":25477694801},{"date":"2025-10-31","current":-8.936138,"twenty":-24.228898,"median":-16.208434,"eighty":-10.01166,"marketCap":27643386896},{"date":"2025-11-07","current":-8.115895,"twenty":-24.0933,"median":-15.983588,"eighty":-9.661913,"marketCap":25090335240},{"date":"2025-11-14","current":-9.615008,"twenty":-24.036348,"median":-15.846935,"eighty":-9.533336,"marketCap":29809078990},{"date":"2025-11-21","current":-8.88084,"twenty":-23.659864,"median":-15.493415,"eighty":-9.411746,"marketCap":27520136126},{"date":"2025-11-28","current":-9.805814,"twenty":-23.032171,"median":-15.270261,"eighty":-9.358381,"marketCap":30496838785},{"date":"2025-12-05","current":-9.522579,"twenty":-22.810207,"median":-15.147164,"eighty":-9.358381,"marketCap":29666872704},{"date":"2025-12-12","current":-9.227769,"twenty":-22.078047,"median":-15.043786,"eighty":-9.232281,"marketCap":28801588916},{"date":"2025-12-19","current":-9.562517,"twenty":-22.024358,"median":-14.816055,"eighty":-9.195431,"marketCap":29916743432},{"date":"2025-12-24","current":-8.86445,"twenty":-21.960012,"median":-14.582474,"eighty":-9.185632,"marketCap":27819193982},{"date":"2026-01-02","current":-8.361415,"twenty":-21.780535,"median":-14.405796,"eighty":-9.071858,"marketCap":26343799029},{"date":"2026-01-09","current":-10.158481,"twenty":-21.573184,"median":-14.143758,"eighty":-9.138635,"marketCap":32085396254},{"date":"2026-01-16","current":-10.130227,"twenty":-21.338723,"median":-13.671075,"eighty":-9.159542,"marketCap":32100133626},{"date":"2026-01-23","current":-9.450777,"twenty":-21.128733,"median":-12.833558,"eighty":-9.159542,"marketCap":29918397524},{"date":"2026-01-30","current":-9.27281,"twenty":-20.989151,"median":-11.556174,"eighty":-9.159542,"marketCap":29489203537},{"date":"2026-02-06","current":-8.834279,"twenty":-20.864442,"median":-11.154997,"eighty":-9.026205,"marketCap":28165855410},{"date":"2026-02-13","current":-9.445101,"twenty":-20.730279,"median":-10.443288,"eighty":-9.076015,"marketCap":30286271904},{"date":"2026-02-20","current":-9.824687,"twenty":-20.674464,"median":-10.43817,"eighty":-9.09489,"marketCap":31458062186},{"date":"2026-02-27","current":-8.771359,"twenty":-20.006759,"median":-10.305855,"eighty":-9.047703,"marketCap":28393379910},{"date":"2026-03-06","current":-8.859488,"twenty":-19.896232,"median":-10.18539,"eighty":-8.969972,"marketCap":28447462538},{"date":"2026-03-13","current":-7.555838,"twenty":-19.630572,"median":-10.144354,"eighty":-8.935093,"marketCap":24373237865},{"date":"2026-03-20","current":-7.859442,"twenty":-19.432697,"median":-9.991099,"eighty":-8.867218,"marketCap":25256587462},{"date":"2026-03-27","current":-8.718949,"twenty":-19.118727,"median":-9.951719,"eighty":-8.854358,"marketCap":25617138318},{"date":"2026-04-02","current":-9.880216,"twenty":-19.012497,"median":-9.885599,"eighty":-8.850342,"marketCap":29168564250},{"date":"2026-04-10","current":-9.180446,"twenty":-18.964111,"median":-9.878849,"eighty":-8.85641,"marketCap":27311727342},{"date":"2026-04-17","current":-9.417233,"twenty":-18.904163,"median":-9.820225,"eighty":-8.842311,"marketCap":28027927148},{"date":"2026-04-24","current":-8.878352,"twenty":-18.860571,"median":-9.805814,"eighty":-8.846908,"marketCap":26425587896},{"date":"2026-04-30","current":-8.372511,"twenty":-18.781003,"median":-9.783435,"eighty":-8.82699,"marketCap":24926391864},{"date":"2026-05-08","current":-7.738947,"twenty":-18.469318,"median":-9.736996,"eighty":-8.785939,"marketCap":23120131584},{"date":"2026-05-15","current":-6.609967,"twenty":-18.384608,"median":-9.691452,"eighty":-8.751075,"marketCap":20699742808},{"date":"2026-05-22","current":-6.440114,"twenty":-18.185423,"median":-9.652725,"eighty":-8.708072,"marketCap":20121739519},{"date":"2026-05-29","current":-6.506712,"twenty":-18.096065,"median":-9.620334,"eighty":-8.669056,"marketCap":20400514838}],"updateTime":1780331235117},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09606\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627261720","title":"中金：國家優化創新藥新藥上市首發價格機制 藥品行業有望迎高質量發展","url":"https://stock-news.laohu8.com/highlight/detail?id=2627261720","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627261720?lang=zh_tw&edition=fundamental","pubTime":"2026-04-16 14:24","pubTimestamp":1776320685,"startTime":"0","endTime":"0","summary":"中金主要观点如下：优化创新药等新上市药品首发价格机制，实行新上市药品企业自评制度政策鼓励对于新上市药品价格制定，区分高水平创新药、改良新药、通用名药等情形。根据真实世界研究结果和临床使用实效，医药企业可在药品首发价格基础上适当调整价格水平。促进创新药多元支付与价格合理形成，拓宽创新药支付渠道。风险因素研发不及预期，创新药核心产品对外合作进展不及预期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU1023057109.AUD","LU2488822045.USD","LU0634319403.HKD","LU2543165471.USD","LU0417516738.SGD","IPOS","BK1191","01276","LU0588546209.SGD","LU0307460666.USD","LU2399975544.HKD","LU2476274308.USD","LU0196878994.USD","HK0000165453.HKD","LU2328871848.SGD","LU0348783233.USD","LU2476274720.SGD","LU2778985437.USD","LU1770034418.SGD","09606","06160","LU0455707207.USD","IE00B543WZ88.USD","HK0000500386.USD","IE00B5MMRT66.SGD","LU2097828631.EUR","09926","LU2097828557.USD","06978","LU1794554557.SGD","LU1961090484.USD","LU2097828805.USD","LU0348766576.USD","LU0561508036.HKD","LU0348784397.USD","LU1719994722.HKD","LU0417516571.SGD","06990","LU0417516902.SGD","01801","LU0502904849.HKD","LU0359202008.SGD","LU2097828714.EUR","BK1588","LU0540923850.HKD","159992","HK0000252160.HKD","LU0348827113.USD","LU0348825331.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627540837","title":"映恩生物－Ｂ(09606)股價上升8.089%，現價港幣$310.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2627540837","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627540837?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 13:05","pubTimestamp":1776229500,"startTime":"0","endTime":"0","summary":"[上升股]映恩生物－Ｂ(09606) 股价在下午01:05比前收市价上升8.089%，现股价为港币$310.0。至目前为止，今日最高价为$310.0，而最低价为$290.2。总成交量为57.362万股，总成交金额为港币$1.715亿。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126133719348_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2604153343/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2604153343/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","HK0000252152.HKD","HK0000252160.HKD","LU2543165471.USD","HK0000500386.USD","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197788137","title":"異動解讀 | 映恩生物-B盤中大漲5.02%，科創板上市計劃提振市場信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1197788137","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1197788137?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 09:33","pubTimestamp":1776216839,"startTime":"0","endTime":"0","summary":"映恩生物-B今日盘中大涨5.02%，引起了市场的广泛关注。消息面上，公司于盘前发布公告，董事会已批准发行人民币股份并在科创板上市的计划。公司拟发行不超过1577.92万股人民币股份，占发行后总股本的15%，募集资金将主要用于新药研发及补充营运资金。分析认为，A股市场对生物医药等硬科技赛道通常给予更高的流动性和估值溢价，映恩生物此次回A计划有望为公司带来价值重估。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627478451","title":"加速全球ADC龍頭價值構建，映恩生物-B(09606)推動「H+A」雙資本平台佈局釋放長投信號","url":"https://stock-news.laohu8.com/highlight/detail?id=2627478451","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627478451?lang=zh_tw&edition=fundamental","pubTime":"2026-04-15 08:00","pubTimestamp":1776211200,"startTime":"0","endTime":"0","summary":"4月13日晚，ADC龙头企业映恩生物-B发布公告宣布：董事会批准了发行人民币股份并在科创板上市的计划。对于映恩生物而言，自2025年6月成功实现港股上市后，此次拟申报科创板上市意味着公司正积极锚向“H+A”双资本平台布局，以进一步拓宽企业融资渠道、支持在研管线的临床推进及技术平台建设。作为全球ADC药物创新研发的前沿领导者之一，映恩生物的技术价值也获得了国际业界的高度认可。目前，双方联合用药的临床进展全球领先。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000500386.USD","BK4080","09606","HK0000252152.HKD","BK1161","BK4231","LU2543165471.USD","HK0000252160.HKD","ADC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627498339","title":"映恩生物－Ｂ(09606)出現大手賣出1.77萬股，成交價$287.0，涉資507.99萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2627498339","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627498339?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 09:21","pubTimestamp":1776129660,"startTime":"0","endTime":"0","summary":"[大手成交]映恩生物－Ｂ(09606)在上午09:21出现大手卖出，成交量为1.77万，成交价为港币$287.0，涉资507.99万。至目前为止，股价升0.28%，今日最高价为$287.0，而最低价为$287.0，总成交量为1.77万股，总成交金额港币$507.99万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT26041484/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT26041484/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["HK0000252152.HKD","LU2543165471.USD","BK1161","09606","HK0000500386.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627520451","title":"映恩生物-B(09606)擬發行人民幣股份於科創板上市 募資不超過67.5億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2627520451","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627520451?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 22:46","pubTimestamp":1776091575,"startTime":"0","endTime":"0","summary":"映恩生物-B(09606)公布，于2026年4月13日，董事会批准于科创板建议人民币股份发行、特别授权及有关事项，须待股东于股东特别大会上批准及获得必要监管批准后，方可作实。 \n人民币股份发行募集资金总额预计将不超过人民币67.5亿元。扣除发行费用后，所得款项净额将全数用于与公司主营业务相关的项目。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_17.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_17.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","CYB","HK0000252152.HKD","CNHmain","IPOS","159982","UCmain","09606","HK0000252160.HKD","MCNHmain","MUCmain","HK0000500386.USD","LU2543165471.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146987932","title":"映恩生物-B：人民幣股份發行所得款項將用於創新藥物研發等用途","url":"https://stock-news.laohu8.com/highlight/detail?id=1146987932","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146987932?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 22:43","pubTimestamp":1776091393,"startTime":"0","endTime":"0","summary":"映恩生物-B宣布，其通过人民币股份发行筹集的资金，将主要用于支持公司创新药物的研发工作，以及其他相关业务发展。这一资金安排旨在进一步推动公司在生物医药领域的创新步伐，提升研发实力和市场竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","09606","HK0000252152.HKD","BK1161","LU2543165471.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626316255","title":"【券商聚焦】海通國際維持映恩生物-B(09606)「優於大市」評級 指其核心管線商業化臨近","url":"https://stock-news.laohu8.com/highlight/detail?id=2626316255","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626316255?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 15:03","pubTimestamp":1775804624,"startTime":"0","endTime":"0","summary":"金吾财讯 | 海通国际发布研报指，映恩生物-B 核心管线商业化临近且下半年数据催化丰富，维持“优于大市”评级，目标价457.74港元。财务方面，公司2025年实现收入18.5亿元人民币，主要来自许可及合作协议收入。研发费用为8.4亿元，同比基本持平。业务进展上，DB-1303在中国的三期临床已达到主要终点并提交上市申请。合作伙伴BioNTech计划年内提交该产品用于子宫内膜癌的上市申请。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/NGJmNWFkZDNlMDY5ZTM0ZDA3ZmU4NjQzMjc2Mzg3NzYxMw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NGJmNWFkZDNlMDY5ZTM0ZDA3ZmU4NjQzMjc2Mzg3NzYxMw==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978675","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626150243","title":"《大行》海通國際予映恩生物(09606.HK)目標價457.74元 評級「優於大市」","url":"https://stock-news.laohu8.com/highlight/detail?id=2626150243","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626150243?lang=zh_tw&edition=fundamental","pubTime":"2026-04-10 10:24","pubTimestamp":1775787840,"startTime":"0","endTime":"0","summary":"海通国际发表研究报告指，映恩生物去年实现收入18.5亿元人民币，按年跌5%，主要来自于许可及合作协议收入。研发费用8.4亿元人民币，按年基本持平。该行结合映恩生物临床管线推进情况，调整公司可能收到来自BioNTech的远期销售分成预测，并调整今年和明年收入预测分别为18亿和17亿元人民币，归母净亏损预测3.7亿元和1.7亿元人民币。该行将其目标价调整至457.74元，维持“优于大市”评级。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250409114928209_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250409114928209_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1516793/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1516793/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626613139","title":"映恩生物(09606.HK)核心產品DB-1303/BNT323上市申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2626613139","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626613139?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 23:56","pubTimestamp":1775750160,"startTime":"0","endTime":"0","summary":"映恩生物－Ｂ(09606.HK) 公布，公司核心产品DB-1303/BNT323基于III期关键临床研究所获得的积极结果，以及与国家药监局药品审评中心的新药上市申请前沟通交流反馈，提交的生物制品新药上市申请已获国家药品监督管理局受理。III期临床试验旨在评估DB-1303相较于T-DM1在既往接受曲妥珠单抗和紫杉烷类治疗的HER2阳性不可切除或转移性乳腺癌患者中的疗效和安全性。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-04-09 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250911164657656_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250911164657656_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1516689/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1516689/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["HK0000252152.HKD","LU2543165471.USD","BK1161","09606","HK0000500386.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106054667","title":"映恩生物宣佈抗HER2 ADC新藥Trastuzumab Pamirtecan治療晚期乳腺癌的BLA獲中國國家藥監局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1106054667","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106054667?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 19:58","pubTimestamp":1775735931,"startTime":"0","endTime":"0","summary":"映恩生物宣布，其针对不可切除或转移性HER2阳性成人乳腺癌的创新抗体偶联药物Trastuzumab Pamirtecan，已正式向中国国家药品监督管理局提交生物制品许可申请，并获受理。此次BLA获受理是基于一项关键性临床研究数据的积极结果。该研究旨在评估Trastuzumab Pamirtecan在经治的HER2阳性晚期乳腺癌患者中的疗效与安全性。若后续审评进展顺利并获得批准，Trastuzumab Pamirtecan将成为映恩生物在肿瘤治疗领域商业化进程中的重要里程碑，为国内HER2阳性乳腺癌患者带来新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252152.HKD","HK0000500386.USD","09606","LU2543165471.USD","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123067387","title":"國家藥監局受理映恩生物DB-1303/BNT323治療HER2陽性乳腺癌的生物製品許可申請","url":"https://stock-news.laohu8.com/highlight/detail?id=1123067387","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123067387?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 18:51","pubTimestamp":1775731872,"startTime":"0","endTime":"0","summary":"映恩生物宣布，其针对HER2阳性乳腺癌的创新疗法DB-1303/BNT323的生物制品许可申请已获中国国家药品监督管理局正式受理。这一关键进展标志着该抗体偶联药物在中国商业化进程中迈出重要一步，有望为HER2阳性乳腺癌患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09606","HK0000500386.USD","LU2543165471.USD","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626618686","title":"映恩生物-B(09606)：DB-1303/BNT323用於不可切除或轉移性HER2陽性成人乳腺癌的新藥上市申請獲得國家藥監局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2626618686","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626618686?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 18:50","pubTimestamp":1775731855,"startTime":"0","endTime":"0","summary":"智通财经APP讯，映恩生物-B 发布公告，基于III 期关键临床研究所获得的积极结果和与国家药监局药品审评中心的新药上市申请前沟通交流反馈，提交的生物制品新药上市申请已获得国家药品监督管理局受理。DB-1303-O-3001试验是一项随机、对照、开放标签、多中心的III期临床试验，旨在评估DB-1303相较于T-DM1在既往接受曲妥珠单抗和紫杉烷类治疗的HER2 阳性不可切除或转移性乳腺癌患者中的疗效和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426647.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","BK4585","BK4566","BK4588","09606","DB","HK0000252152.HKD","IPOS","BK4552","LU2543165471.USD","HK0000500386.USD","BK4118","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181868709","title":"映恩生物-B3月股份變動月報表，股本小幅增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1181868709","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181868709?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 18:41","pubTimestamp":1775731275,"startTime":"0","endTime":"0","summary":"映恩生物-B于2026年4月9日发布截至2026年3月31日的股份变动月报表。根据公告，公司本月注册股本仍为200,000,000股，面值USD 0.0001，注册股本金额维持20,000美元不变。报告期内，已发行股份由上月底的90,137,714股增至90,238,014股，新增发行股份共100,300股，均来自公司首次公开发售前股权激励计划的期权行使。公司当月无股份回购或注销活动，库存股份保持为零。截至本月末，公司已发行股份总数为90,238,014股，股本规模小幅增加。公告由联席公司秘书袁佳丽签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625980889","title":"映恩生物－Ｂ(09606)出現大手成交300萬股，成交價$301.0，涉資9.03億","url":"https://stock-news.laohu8.com/highlight/detail?id=2625980889","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625980889?lang=zh_tw&edition=fundamental","pubTime":"2026-04-08 09:01","pubTimestamp":1775610060,"startTime":"0","endTime":"0","summary":"[大手成交]映恩生物－Ｂ(09606)在上午09:01出现大手成交，成交量为300万，成交价为港币$301.0，涉资9.03亿。至目前为止，股价无升跌，今日最高价为$301.0，而最低价为$301.0，总成交量为300万股，总成交金额港币$9.03亿。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2604082/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2604082/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["09606","HK0000252152.HKD","HK0000252160.HKD","LU2543165471.USD","HK0000500386.USD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112073873","title":"異動解讀 | 生物醫藥板塊全線走高帶動，映恩生物-B盤中大漲6.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=1112073873","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112073873?lang=zh_tw&edition=fundamental","pubTime":"2026-03-31 09:58","pubTimestamp":1774922310,"startTime":"0","endTime":"0","summary":"映恩生物-B今日盘中大涨6.11%，引起了市场的广泛关注。消息面上，港股生物医药股今日全线走高，映恩生物-B的上涨与板块整体强势表现密切相关。其中，昭衍新药在公布业绩后股价升逾14%，显著提振了市场对生物医药板块的情绪，进而带动了包括映恩生物-B、翰森制药、药明生物及药明康德在内的多只相关个股同步上涨。此次生物医药板块的普涨行情，反映了市场对该行业近期发展态势的关注与积极预期。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154463260","title":"異動解讀 | 中金維持跑贏行業評級，映恩生物-B盤中大漲6.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154463260","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154463260?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 10:36","pubTimestamp":1774579011,"startTime":"0","endTime":"0","summary":"映恩生物-B今日盘中大涨6.41%，引起了市场的广泛关注。消息面上，中金公司发布研究报告，维持映恩生物-B“跑赢行业”评级，目标价430港元不变，较当前股价有63.4%的上行空间。报告指出，公司2025年收入达18.5亿元，超出该行预期，主要得益于研发合作报销收入超预期。此外，公司的核心管线全球开发进展顺利。公司与BioNTech的合作联用试验也预计将在2026年陆续取得数据，后续管线催化事件丰富。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622786816","title":"中金：維持映恩生物-B(09606)跑贏行業評級 目標價430港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622786816","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622786816?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 10:28","pubTimestamp":1774578495,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，基于DCF模型，维持映恩生物-B跑赢行业评级和目标价430港元不变，较当前股价有63.4%的上行空间。中金主要观点如下：第一梯队管线全球开发全速推进根据公司公告，截至2025年，公司累计完成全球临床入组约3,200例患者，其中2025年新增入组约1,200人，约50%来自中国以外地区，体现高效执行力。公司DB-2304已经完成2a期试验的首例患者给药，建议关注自免ADC这一创新概念验证。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420217.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621405808","title":"映恩生物－Ｂ(09606)出現大手賣出6.7萬股，成交價$258.0，涉資1.729千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2621405808","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621405808?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 13:04","pubTimestamp":1774328640,"startTime":"0","endTime":"0","summary":"[大手成交]映恩生物－Ｂ(09606)在下午01:04出现大手卖出，成交量为6.7万，成交价为港币$258.0，涉资1.729千万。至目前为止，股价跌3.632%，今日最高价为$277.2，而最低价为$254.6，总成交量为75.137万股，总成交金额港币$1.97亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603245913/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2603245913/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["HK0000500386.USD","BK1161","LU2543165471.USD","09606","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621039428","title":"映恩生物(09606.HK)委任首席財務官","url":"https://stock-news.laohu8.com/highlight/detail?id=2621039428","media":"阿斯达克财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621039428?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 09:22","pubTimestamp":1774315320,"startTime":"0","endTime":"0","summary":"映恩生物-B(09606.HK) 公布，委任张韶壬为公司首席财务官，自上日(23日)起生效。(ca/da)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-23 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20250409114929116_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20250409114929116_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511696/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511696/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["HK0000252160.HKD","09606","HK0000500386.USD","LU2543165471.USD","HK0000252152.HKD","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":2,"totalSize":168,"code":"91000000","status":"200"}]}}